Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Milnacipran

All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).

Trial Locations (1)

90095

UCLA Semel Institute, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

University of California, Los Angeles

OTHER